Form 8-K - Current report:
SEC Accession No. 0001193125-25-152767
Filing Date
2025-06-30
Accepted
2025-06-30 16:29:15
Documents
12
Period of Report
2025-06-27
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d109611d8k.htm   iXBRL 8-K 34636
  Complete submission text file 0001193125-25-152767.txt   152647

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ikt-20250627.xsd EX-101.SCH 2857
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20250627_lab.xml EX-101.LAB 18738
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20250627_pre.xml EX-101.PRE 11713
14 EXTRACTED XBRL INSTANCE DOCUMENT d109611d8k_htm.xml XML 3765
Mailing Address 1000 N. WEST STREET, SUITE 1200 WILMINGTON DE 19801
Business Address 1000 N. WEST STREET, SUITE 1200 WILMINGTON DE 19801 (302) 295-3800
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 251092459
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)